ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis

被引：0
|
作者：
Strand, V. [1 ]
van der Heijde, D. [2 ]
Zerbini, C. A. F. [3 ]
Connell, C. A. [4 ]
Gruben, D. [4 ]
Riese, R. [4 ]
Wallenstein, G. [4 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Leiden Univ, Med Ctr, Leiden, Netherlands
[3] Ctr Paulista Invest Clin, Sao Paulo, Brazil
[4] Pfizer Inc, Groton, CT 06340 USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2334
引用
收藏
页码：S996 / S997
页数：2
相关论文
共 50 条
  • [21] Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
    Vibeke Strand
    Arthur Kavanaugh
    Alan J. Kivitz
    Désirée van der Heijde
    Kenneth Kwok
    Ermeg Akylbekova
    Arif Soonasra
    Mark Snyder
    Carol Connell
    Eustratios Bananis
    Josef S. Smolen
    Rheumatology and Therapy, 2018, 5 : 341 - 353
  • [22] EFFECTS OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO DMARDS
    Li, Z.
    An, Y.
    Li, G.
    Wang, L.
    Kwok, K.
    Wu, Q.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 285 - 286
  • [23] Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
    Strand, Vibeke
    van Vollenhoven, Ronald F.
    Lee, Eun Bong
    Fleischmann, Roy
    Zwillich, Samuel H.
    Gruben, David
    Koncz, Tamas
    Wilkinson, Bethanie
    Wallenstein, Gene
    RHEUMATOLOGY, 2016, 55 (06) : 1031 - 1041
  • [24] Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
    Vibeke Strand
    Joel Kremer
    Gene Wallenstein
    Keith S. Kanik
    Carol Connell
    David Gruben
    Samuel H. Zwillich
    Roy Fleischmann
    Arthritis Research & Therapy, 17
  • [25] Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
    Strand, Vibeke
    Kremer, Joel
    Wallenstein, Gene
    Kanik, Keith S.
    Connell, Carol
    Gruben, David
    Zwillich, Samuel H.
    Fleischmann, Roy
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [26] Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
    Genovese, Mark
    Westhovens, Rene
    Meuleners, Luc
    Van der Aa, Annegret
    Harrison, Pille
    Tasset, Chantal
    Kavanaugh, Arthur
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [27] Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
    Mark Genovese
    Rene Westhovens
    Luc Meuleners
    Annegret Van der Aa
    Pille Harrison
    Chantal Tasset
    Arthur Kavanaugh
    Arthritis Research & Therapy, 20
  • [28] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate, in Patients with Active Rheumatoid Arthritis with An Inadequate Response to Tumor Necrosis Factor-Inhibitors: A 6-Month Phase 3 Study.
    Burmester, Gerd-Ruediger
    Blanco, R.
    Charles-Schoeman, C.
    Wollenhaupt, J.
    Zerbini, C. A. F.
    Benda, B.
    Gruben, D.
    Wallenstein, G.
    Krishnaswami, S.
    Zwillich, S. H.
    Koncz, T.
    Bradley, J. D.
    Mebus, C. A.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S279 - S279
  • [29] TOFACITINIB WITH AND WITHOUT METHOTREXATE VERSUS ADALIMUMAB WITH METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS FROM ORAL STRATEGY, A PHASE 3B/4 RANDOMISED TRIAL
    Fleischmann, R.
    Mysler, E.
    Hall, S.
    Kivitz, A.
    Moots, R.
    Luo, Z.
    Tatulych, S.
    DeMasi, R.
    Soma, K.
    Zhang, R.
    Takiya, L.
    Mojcik, C.
    Krishnaswami, S.
    Menon, S.
    Smolen, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 149 - 150
  • [30] Assessment of patient-reported outcomes from a double-blind trial of etanercept and methotrexate combination in early active rheumatoid arthritis: The COMET trial
    Durez, P.
    Emery, P.
    Hall, S.
    Koenig, A.
    Sato, R.
    Singh, A.
    Robertson, D.
    Freundlich, B.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S457 - S457
12345